Catalan Institute of Nanoscience and Nanotechnology (ICN2)

Dr. Christian Brander and Dr. Mala Maini Join World-class Scientific Advisory Board of AstriVax

Retrieved on: 
Tuesday, August 22, 2023

Together with the other distinguished vaccine development experts on the company’s scientific advisory board, they will support AstriVax in advancing its innovative plug-and-play vaccine platform.

Key Points: 
  • Together with the other distinguished vaccine development experts on the company’s scientific advisory board, they will support AstriVax in advancing its innovative plug-and-play vaccine platform.
  • Leuven, Belgium, August 21, 2023 – AstriVax is pleased to announce that Dr. Christian Brander and Dr. Mala Maini have agreed to join the company’s scientific advisory board.
  • Hanne Callewaert, Ph.D., co-founder and CEO of AstriVax, said: “I am grateful that Christian and Mala have agreed to join our scientific advisory board.
  • I’m also thrilled to have award-winning viral immunologist Mala Maini on board, as her work on hepatitis B and her expertise on improving immunotherapeutic outcomes are invaluable to AstriVax.

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

Retrieved on: 
Tuesday, May 23, 2023

ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately. Dr. Alemany will oversee Theriva’s discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board.

Key Points: 
  • ROCKVILLE, Md., May 23, 2023 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately.
  • Dr. Alemany will oversee Theriva’s discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board.
  • “Ramon is an internationally recognized expert in oncolytic adenoviruses and as Co-Founder of VCN Biosciences, is uniquely suited to lead Theriva’s discovery program through its next critical phase of development,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • Combining novel viral payloads with the proprietary Albumin Shield technology to protect systemically administered oncolytic viruses from the host immune system has tremendous potential for our pipeline.”

REVEAL GENOMICS®´ Breakthrough Technology Enters the Liquid Biopsy Field in Oncology

Retrieved on: 
Thursday, March 9, 2023

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced today a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer.

Key Points: 
  • REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced today a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer.
  • Analysis of cell-free DNA (cfDNA), present in body fluids such as plasma, is broadly known as liquid biopsy.
  • In oncological patients, cfDNA contains a fraction of tumor-derived genomic material (ctDNA), that has been proven as a valuable resource to identify tumor-borne genetic alterations.
  • Firstly, REVEAL GENOMICS®' proprietary machine-learning multi-gene signatures were applied in plasma and linked to DNA/RNA/protein data from tumor tissue (paired samples).

REVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY

Retrieved on: 
Thursday, March 9, 2023

The assay allows opportunities for discovering new cancer-associated phenotypes and the ability to detect these clinically relevant tumor phenotypes using ctDNA.

Key Points: 
  • The assay allows opportunities for discovering new cancer-associated phenotypes and the ability to detect these clinically relevant tumor phenotypes using ctDNA.
  • BARCELONA, Spain, March 9, 2023 /PRNewswire/ -- REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced today a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer.
  • Analysis of cell-free  DNA (cfDNA), present in body fluids such as plasma, is broadly known as liquid biopsy.
  • Firstly, REVEAL GENOMICS®' proprietary machine-learning multi-gene signatures were applied in plasma and linked to DNA/RNA/protein data from tumor tissue (paired samples).

REVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY

Retrieved on: 
Thursday, March 9, 2023

The assay allows opportunities for discovering new cancer-associated phenotypes and the ability to detect these clinically relevant tumor phenotypes using ctDNA.

Key Points: 
  • The assay allows opportunities for discovering new cancer-associated phenotypes and the ability to detect these clinically relevant tumor phenotypes using ctDNA.
  • BARCELONA, Spain, March 9, 2023 /PRNewswire/ -- REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced today a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer.
  • Analysis of cell-free  DNA (cfDNA), present in body fluids such as plasma, is broadly known as liquid biopsy.
  • Firstly, REVEAL GENOMICS®' proprietary machine-learning multi-gene signatures were applied in plasma and linked to DNA/RNA/protein data from tumor tissue (paired samples).

AOP Health Starts Research for Leukemia Treatment

Retrieved on: 
Monday, August 1, 2022

VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria.

Key Points: 
  • VIENNA, Austria, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The AOP Health Group (AOP Health) is a European pioneer for integrated therapies for rare diseases and in critical care headquartered in Vienna, Austria.
  • In early July, AOP Health signed an agreement with Leukos Biotech, a spin-off company founded by the Barcelona-based Josep Carreras Leukaemia Research Institute.
  • At first, AOP Health will focus on the development of treatment options for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
  • The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (AOP Health).

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

Retrieved on: 
Tuesday, January 11, 2022

Dr. Limns broad scientific and clinical research experience in hematology and oncology will be key in developing Oryzons clinical programs.

Key Points: 
  • Dr. Limns broad scientific and clinical research experience in hematology and oncology will be key in developing Oryzons clinical programs.
  • She joins Oryzon from Deciphera Pharmaceuticals, a Nasdaq listed company, where she was Senior Director and Global Program Leader of several assets.
  • Prior to that, she held roles of increasing responsibility at Millenium Pharmaceuticals and Takeda, her last as the Head of the Oncology Pipeline, Global Medical Affairs at Takeda.
  • Dr. Carlos Buesa, President and CEO of Oryzon said: Dr. Limn is an outstanding professional with enormous molecular and clinical knowledge in oncology.

Pittcon Conference Highlights Top Laboratory & Analytical Science Sectors

Retrieved on: 
Tuesday, November 30, 2021

The field of laboratory science is constantly changing, states Pittcon 2022 President Eli Absey.

Key Points: 
  • The field of laboratory science is constantly changing, states Pittcon 2022 President Eli Absey.
  • Pittcon will always reflect the most modern discoveries, insights, and advancements within our field.
  • Pittcon is a dynamic, transnational conference and exposition on laboratory science, a venue for presenting the latest advances in research and scientific instrumentation, and a platform for continuing education and science-enhancing opportunity.
  • Pittcon is a catalyst for the exchange of information, a showcase of the latest advances in laboratory science, and a venue for international connectivity.